Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 10 Oct - Allotment of 23,374 Equity Shares under the Jeena Sikho Lifecare Limited Employee Stock Option Scheme 2024 ("ESOS 2024")
Source: Bse
Jeena Sikho Lifecare Limited (JSLL)
Micro CapConsumer stocks · Micro cap · NSE
Jeena Sikho Lifecare Limited (JSLL) is an Indian Ayurveda healthcare provider offering services through 120+ clinics & hospitals and a portfolio of 330+ Ayurveda products. It operates on a capital-light, hub-and-spoke model, focusing on holistic, drug-free wellness and aims to address root causes of illness.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result16 Aug, 12:31 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags15 Aug 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Consumer P/E 22.2 (n=441)
Technical timing lens
Trend score and candlestick chart
27Bearishfull bear SMA stack · SMA20 -12.0% / mo · RSI oversold · MACD − · near 52W low · sector -3.7pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 36
Sector 3M: -9.3% vs Nifty 500 -5.6%
Consumer FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
JSLLD candles · FIT view-41.7%Latest close ₹369.75 on 2026-10-19
Bar
-5.7%
RSI
22
MACD hist
-6.00
52W pos
2%
2026-10-19O ₹392.00H ₹392.00L ₹365.10C ₹369.75Vol 5.5L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
JSLLNifty Consumer DurablesNifty 500
- JSLL
- -35.7%
- Nifty 500
- -5.6%
- Nifty Consumer Durables
- -9.7%
- Vs Nifty 500
- -30.1 pp
Chart stats
19 Oct 2026- From 52W high
- -55.7%
- 52W range position
- 2%
- ATR (14)
- 5.8%
- Volume vs 20D
- 0.51x
- Avg traded value
- ₹45.8 Cr
- 20D price channel
- ₹359.8 - ₹530.8
₹835
₹359.8 - ₹835
₹21.5
Latest completed session
20-session average
48.2% annualized volatility
Research snapshot
What the evidence says now
Strong fundamentals, management evidence is still limited to a financial-only Trust Lite signal, but price trend argues for patience. Suitable for staggered entry or watchlist confirmation rather than aggressive buying.
Strong U-Score but weak trend: timing is not confirming the thesis.
Suggested next step
Add to watchlist
Fundamental setup is interesting, but technical confirmation is weak.
U-Score
Legacy · DEEP VALUE75
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average52
Revenue +28.7% · PAT +29.4% YoY
Technical
Bearish27
Price trend and sector-relative-strength timing.
Valuation
Legacy model+41.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence81
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 52/100margin compression · Rev +29% YoY · PAT +29% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹224 Cr | +28.7% | +3.7% |
| EBITDA | ₹92 Cr | +16.5% | +17.9% |
| Operating margin | 41.0% | -400 bps | +500 bps |
| PAT | ₹66 Cr | +29.4% | +46.7% |
| PAT margin | 29.5% | +15 bps | +863 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 20.40
- P/B
- 10.32
- EV/EBITDA
- 11.91
- Market Cap
- 4828.00Cr
Profitability
- ROE
- 61.30%
- ROCE
- 64.40%
- ROA
- 35.01%
- Dividend Y
- 1.16%
Growth (CAGR)
- Revenue 5Y
- 55.11%
- EPS 5Y
- 115.22%
- Revenue 3Y
- 58.00%
- EPS 3Y
- 88.00%
Balance Sheet
- Debt/Equity
- 0.27
- Interest Coverage
- 24.20×
- Altman Z
- 10.08
- Book Value
- 37.60
Cash Flow
- FCF Yield
- 1.08%
- FCF Positive Y
- 2/5
- OCF
- 254.00 Cr
- EPS TTM
- 19.03
Shareholding
- Promoter Hold
- 63.62%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 6%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 801+70.8% vs prev
Net Profit
₹ CrLatest: 222+177.5% vs prev
Return on Equity
%Latest: 47.5+52.1% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 22. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~13.6% over last month) — short-term momentum negative.
- RSI(14) at 22 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 75 · legacy U-Score band DEEP VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 75 · legacy U-Score band DEEP VALUE · valuation evidence and comparable companies
Top Setup
Fundamental score breakdown
U band · DEEP VALUEValuation10/30
Growth23/25
Quality20/20
Balance Sheet11/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
75
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
75/100 · legacy band DEEP VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 41.6%.
- Quality contributes 20/20 to the score.
Main drags
- Valuation is weaker at 10/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
- Balance sheet is weaker at 11/15; verify the latest quarterly trend.
Sector valuation model
Consumer valuation: PE/PEG and brand-quality premium
Consumer franchises can deserve higher multiples, but only when growth quality supports them.
Primary lens
PE and PEG relative to growth, ROE, margins, and brand strength.
Secondary checks
Volume growth, pricing power, distribution, same-store or category growth.
Main risk check
Premium valuation needs durable growth and margin resilience.
PE
20.4
PB
10.3
EV/EBITDA
11.9
ROE
61.3%
ROCE
64.4%
FCF Yield
1.1%
Debt/Equity
0.3
MoS
+41.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
75
Previous: 75
Legacy U-Score band
DEEP VALUE
Previous: DEEP VALUE
Margin of safety
+41.6%
Previous: +41.6%
Score history
12 stored score snapshots. Latest stored move: +3 points.
20 Oct 2026
v4.3-runtime-valuation
71
72
72
72
72
72
72
72
72
72
72
75
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹126.88
-191.4% MoS
Growth-justified P/E
33.3
Growth-justified Value
₹633.7
+41.6% MoS
PEG
0.20
Comparable companies
Peers
Business-comparable peers in Consumer — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MADHAVBAUG
SME
Vaidya Sane Ayurved Laboratories Ltd.
Healthcare Services
match 136
51
18.8
12.0%
+59%
FAIR VALUE
SPARC
Micro
Sun Pharma Advanced Research Company Limited
Healthcare Services
match 122
56
3.8
279.0%
+11%
FAIR VALUE
SUPRIYA
Micro
Supriya Lifescience Limited
Healthcare Services
match 119
52
35.9
19.1%
+19%
FAIR VALUE
RPGLIFE
Small
RPG Life Sciences Limited
Healthcare Services
match 118
57
41.0
19.3%
+13%
FAIR VALUE
UNICHEMLAB
Small
Unichem Laboratories Limited
Healthcare Services
match 117
66
30.6
3.2%
+74%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis under stressReviewed 2026-06-10T07:08:48.936Z
Management commentary snapshot
FY26 Revenue surged 71% YoY to INR 801.35 Cr, with PAT up 178% YoY. Q4FY26 revenue grew 55% YoY but declined 3% QoQ. Q4 EBITDA margin moderated to 36% from 45% QoQ due to one-off provisions.
While annual growth is robust, the sequential decline in Q4 revenue and significant margin compression due to 'one-off' provisions raise concerns about operational consistency and underlying profitability trends. The capital-light model and expansion are positive, but the impact of these provisions needs closer scrutiny for future quarters.
Current business mix
Revenue by vertical (FY26)
Latest issuer-disclosed distribution across 2 reported categories.
Ayurveda Healthcare Services48.0%
Ayurveda Healthcare Products52.0%
Growth engines
Expanding Service Reach
Expansion pipeline remains robust, with total bed capacity increasing to 2,861 and 2,300 beds currently operational across 120+ clinics & hospitals.
Higher Patient Volumes
IPD volumes grew 65% to 40,454 and OPD volumes grew 69% to ~5.7 lakh patients in FY26, supported by strong patient inflows.
Product Diversification & Reach
Ayurveda Healthcare Products business benefits from product diversification initiatives and expanding customer reach, registering 93% growth in Q4.
Capital-Light Business Model
Low CAPEX per bed (~₹3-4 lakh for 100-bed facility) and a mix of own & franchise assets enable rapid scaling and superior ROCE (46% 3Y average).
Capacity and execution
Operational Bed Capacity
Total bed capacity increased to 2,861, with 2,300 beds currently operational. Recently added 561 beds.
Beds in Pipeline
445 beds are in the pipeline, expected to enhance capacity and support sustained volume-led growth.
Tailwinds
Rising Awareness of Ayurveda
Continued rise in awareness and acceptance of Ayurvedic healthcare solutions across India is strengthening demand visibility.
Government Empanelments
Empanelled for treatment of government employees of Uttar Pradesh, Bihar, Haryana, Punjab, CGHS, CAPF, ECHS, and other entities.
Headwinds
One-off Provisions Impacting Q4 Margins
Sequential moderation in Q4FY26 margins was due to higher provisioning for labour code amendments, ESOP, and performance-linked bonuses (~INR 21 Cr total).
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is essential to assess the overall growth trajectory and annual performance, especially for a rapidly expanding business. QoQ comparison is crucial to understand sequential momentum, the impact of one-off provisions on Q4 margins, and operational efficiency trends.
Sector KPIs management disclosed
Revenue from Operations (FY26)
Revenue from Operations grew 71% YoY for FY26 to INR 80,135 Lakhs.
Profit After Taxes (FY26)
Profit After Taxes grew 178% YoY for FY26 to INR 22,218 Lakhs.
EBITDA Margin (FY26)
For FY26, EBITDA margins improved to 44% compared to 30% in FY25, reflecting operating leverage and scalability.
EBITDA Margin (Q4FY26)
EBITDA margin was 36% in Q4FY26, a sequential moderation from 45% in Q3FY26 due to higher provisioning.
Management forward view
Continued Growth Momentum
Jeena Sikho continued its growth momentum in Q4FY26, delivering strong operational and financial performance across both verticals.
Robust Expansion Pipeline
Our expansion pipeline remains robust, with additions expected to enhance capacity, improve regional penetration, and support sustained volume-led growth.
Focus on Long-Term Value Creation
Efforts like the Jeena Sikho Health Card reinforce our focus on long-term value creation and patient loyalty.
Shareholder Rewards
The Board recommended a final dividend of Rs. 4.50 per equity share for FY26, reflecting confidence and focus on rewarding shareholders.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 36% (Q4FY26) | Stabilization and recovery of margins in subsequent quarters, confirming the 'one-off' nature of Q4 provisions. |
| Operational Bed Capacity & Utilization | 2,300 operational beds (FY26) | Ramp-up of the 445 beds in pipeline and sustained improvement in occupancy levels across existing facilities. |
| Patient Volumes (IPD & OPD) | 40,454 IPD, 5.7 lakh OPD (FY26) | Continued strong growth in patient inflows, indicating sustained demand and effective market penetration. |
| Jeena Sikho Health Card Rollout | Trial phase with encouraging early response | Successful full-scale rollout and its measurable impact on patient loyalty, referral benefits, and ecosystem integration. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
81Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 96th percentile within Consumer. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
34 docs text-extracted · 10 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
93rd percentile
overall median 67 · Consumer: 96th pctile, median 66 · Micro: 86th pctile, median 73
Evidence depth
Financial-only
34 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
77
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 63.6%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.8%.
- ▸ROCE is 64.1%.
Trust risks
- ▸OPM spread across recent quarters is 22%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Jeena Sikho Lifecare Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep - Management will join Bharat Connect Conference on 29 September 2026 via virtual meeting.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Sep - Copy of Newspaper Publication of Notice of 9th AGM, E-Voting Information and Cut-off Date.
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement Under Regulation 30 -Proposal For Establishment Of A New Day Care Clinic In Ayodhya, Uttar Pradesh. 11 Jun - Jeena Sikho Lifecare plans a new Ayodhya day care clinic by August 2026 with Rs.50 lakh investment.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 15 Jul - Board approved CS resignation, new CS, three director appointments, and two whole-time directors effective 15 July 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Change in Management 15 Jul - Board appointed new CS, two independent directors, and two Whole Time Directors; existing CS resigned.
Source: Bse
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Bse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 20 Aug - Q1 FY27 revenue rose 29% to ₹224.4 crore; private-pay IPD admissions grew 33%.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Aug - Submission of Newspaper Advertisement Clipping of Extract of the Unaudited (Standalone and Consolidated) Financial Results for the Quarter ended June 30, 2026.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.